Published in MD Week, August 10th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at DUSA Pharmaceuticals.
Report 1: DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Levulan(R) (aminolevulinic acid HCl) Photodynamic Therapy (PDT) for the treatment of esophageal dysplasia. This disease occurs in some patients with Barrett's esophagus, a leading cause of esophageal cancer. The incidence of esophageal cancer is one of the most rapidly growing in the U.S., with more than...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of MD Week